AbbVie appoints Roopal Thakkar as Chief Scientific Officer

AbbVie announced that Roopal Thakkar, who currently serves as senior vice president, Chief Medical Officer, global therapeutics has been appointed to the position of executive vice president, research & development and Chief Scientific Officer. In this position, Thakkar will lead the company’s global R&D organization of more than 14,000 team members across all phases of discovery and development, including therapeutics and aesthetics. Thomas J. Hudson, who currently serves as AbbVie’s senior vice president, Chief Scientific Officer, global research, will retire from AbbVie. Dr. Hudson joined AbbVie in 2016 overseeing oncology discovery and early development before assuming the role of vice president, discovery research. He was appointed to the role of chief scientific officer in 2019. Roopal Thakkar serves as executive vice president, research & development, chief scientific officer at AbbVie. In this role, he leads the company’s R&D organization of more than 14,000 team members around the world and is focused on driving pipeline advancement across therapeutics and aesthetics. Thakkar is also responsible for the six major R&D centers of excellence located across the United States, Germany and Japan. He joined Abbott/AbbVie in 2003 as part of the Physician Development Program.